Aprecia's compression-free 3DP manufacturing platform and Glatt’s multiparticulate technologies offer solutions to pharmaceutical dosage design challenges.
Glatt Pharmaceutical Services and Aprecia announced on Feb. 23, 2021 a joint effort to accelerate and expand the use of Glatt's multiparticulate technologies through Aprecia's ZipDose technology for 3DP manufacturing. The collaboration will advance manufacturing solutions for oral pharmaceutical design challenges that are not addressed by conventional oral solid-dosage manufacturing. The collaboration will initially target existing products for modified release brand-line extensions as well as new chemical entities through accelerated clinical development and patient-focused dosage forms.
"Aprecia has taken a complete approach for partnering with pharmaceutical clients from early product development through FDA commercial manufacturing with their patent-protected 3DP platform," said Philippe Tschopp, head of Business Development for Glatt Pharmaceutical Services, in the press release.
"The purpose of this agreement is to provide our clients more design options, which provide benefits such as modified release, bioavailability enhancement, taste masking, improved solubility, or API stabilization in a patient-preferred dosage form," said Aprecia CEO, Chris Gilmore, in the press release.
Source: Aprecia
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
How Smart Technology is Helping Reach Sustainability Goals in Drug Packaging
June 7th 2025Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers align with sustainability goals, according to Sheikh Akbar Ali, general manager and head of Development and Technology for ACG Packaging Materials.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.